COVID-19-related premature ovarian insufficiency: case report and literature review.

Objective: The aim of this study is to present the case report of a 36-year-old woman developing premature ovarian insufficiency (POI) after COVID-19 and review the literature referring to the possible impact of SARS-CoV-2 infection on female reproduction.

Methods: A 36-year-old nulligravida with normal menstrual cycles, non-smoker, with a normal body mass index and no pelvic surgery or oncological treatment in her medical history presented to the Infertility Center of the Institute of Mother and Child in Warsaw after a year of unsuccessful attempts to get pregnant. During diagnostic process she was affected by COVID-19 with a mild manifestation and thereafter she presented amenorrhea with intense hot flushes.

Psychiatric History and Overactive Bladder Symptom Severity in Ambulatory Urogynecological Patients.

Introduction And Hypothesis: A link between psychiatric comorbidities and overactive bladder symptomatology has been suggested by preclinical and clinical studies. Given this, we hypothesized that a psychiatric history and current treatment with psychotropic medications could be related to the severity of overactive bladder and incontinence symptoms in patients referred to a tertiary care urogynecological center.

Methods: One hundred and twenty-seven female patients diagnosed with an overactive bladder were screened for a lifetime history of psychiatric disorders and the type and number of psychotropic medications currently taken.

[Diabetes insipidus in pregnancy--a case report].

Diabetes insipidus is caused by insufficient secretion of vasopressin (ADH) or by an inability of the kidneys to respond to ADH. Pregnancy-associated DI occurs rarely but is connected with severe complications such as preeclampsia and hepatic function abnormalities. The following paper presents the case of a 36-year-old patient who had been diagnosed with diabetes insipidus in the 34th week of pregnancy.

The C677T mutation in methylenetetrahydrofolate reductase gene, plasma homocysteine concentration and the risk of coronary artery disease.

Background: The C677T mutation in methylenetetrahydrofolate reductase (MTHFR) gene is one of the causes of an elevated homocysteine plasma concentration and is probably one of the atherosclerotic risk factors.

Aim: To assess the relationship between the presence of the MTHFR gene mutation, plasma homocysteine concentration and the risk of coronary artery disease (CAD).

Methods: The study group consisted of 120 consecutive patients (78% were male, mean age 59.

[Evaluation of the precision of the Friedewald's formula for the calculation of low density lipoprotein cholesterol concentration in serum].

The low density lipoproteins (LDL) is one of the important risk factor of coronary heart disease. Evaluation of LDL by direct method of ultracentrifugation (U-LDL), which is the most proper one, is not available in standard laboratories. Instead the Friedewald's formula is commonly used (F-LDL), which calculates level of LDL applying the values of fasting total cholesterol (CH), cholesterol of high density lipoproteins (HDL) and triglicerydes (TG).

[Total serum cholesterol and cholesterol lipoprotein fractions in random sample of Warsaw population].

The aim of the study was to evaluate the level of lipid risk factors in a random sample of Warsaw population aged 35-64 years, 764 men and 775 women, were screened within framework of the Pol-MONICA Warsaw Study. The lipids were determined by enzymatic methods in laboratory controlled by CDC Lipid Standardization Program in Atlanta. In the screened sample the observed levels of total cholesterol (5.

[Dyslipoproteinemia in primary hypertension].

The aim of the study was the estimation of the lipid profile and prevalence of dyslipoproteinemia in patients with essential hypertension. The study group consisted of 108 outpatients (61 men and 47 women) with mild to moderate hypertension (HT), aged 35-64, who did not receive antihypertensive drugs for at least four weeks. The matched controls (MC) were randomly chosen for each HT patient from population of Warsaw inhabitants, covered by Pol-MONICA II screen.

[Lipid risk factors of coronary heart disease during longterm observation of a Warsaw Pol-Monica population-based cohort].

The aim of the study was searching for explanatory variables of high mortality from coronary heart disease (CHD) observed in Poland, with special regards to lipid risk factors, which were determined in a population of Warsaw Pol-MONICA Project. From the randomly selected cohort of Warsaw population, consisted of 348 men and 351 women, aged 35-64 at baseline, the fasting lipid levels were determined three times in 270 men and 266 women. The first study was performed in 1984 year, second in 1988 and third in 1993.

Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.

We investigated the effects of long-term testosterone replacement in hypogonadal and elderly men on lipids and lipoproteins. Twenty-two men with initial serum testosterone concentrations below 3.5 ng/ml took part in the study: 11 with hypopituitarism (1st group) and 11 otherwise healthy elderly men with low testosterone levels (2nd group).

Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease.

Objectives: The purpose of the study was to establish plasma levels of insulin, ovarian sex hormones and dehydroepiandrosterone sulfate (DHEA-S) and to evaluate their correlations with lipids in premenopausal women with angiographically demonstrated coronary stenosis.

Design: Differences in plasma levels of insulin, ovarian sex hormones, DHEA-S and lipids between groups were compared by analysis of variance.

Setting: From January 1993 until December 1993 patients were diagnosed in the Outpatient Clinic of the Department of Endocrinology Medical Centre for Postgraduate Education, Warsaw.

[Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].

Analysis of the efficacy and tolerability of gemfibrozil (Gevilon-Parke Davis) was performed including 29 patients aged 19-69 years with primary hyperlipoproteinemia (HLP) type IIb-16 persons, IV-13 persons. All patients got dietary recommendations and received gemfibrozil 450-900 mg/day for 3 months. In both types of HLP a significant reduction of serum cholesterol (TCh)--15.

Effects of transdermal 17 beta-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women.

Objectives: The purpose of the study was to evaluate the effect of transdermal 17 beta-oestradiol with oral progestogen on the plasma levels of lipids, lipoproteins and apolipoproteins in hypercholesterolaemic postmenopausal women.

Design: During 6 months of replacement therapy with transdermal 17 beta-oestradiol combined with oral progestogen, plasma lipids, lipoproteins and apolipoproteins after 3 and 6 months were measured and compared with pretreatment values by Student's t-test.

Setting: From January 1992 until September 1992 patients were diagnosed and treated in an out-patient clinic of the Department of Endocrinology Medical Centre for Postgraduate Education, Warsaw.

[Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].

The aim of the study was to investigate the effect of a new selective alpha 1-adrenoreceptor blocker doxazosin on blood pressure, serum lipids and lipoproteins in patients with essential hypertension. The study was done in 32 out-patients with mild-to-moderate hypertension (22 men and 10 women, mean age 45.6 +/- 10.

[Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].

The effect of six months' treatment with bezafibrate (400-600 mg daily) on serum lipids, lipoproteins and apolipoproteins concentrations was investigated in 32 patients with primary hyperlipoproteinemia (HLP) type IIa, IIb and IV. In all types of HLP the reduction of serum cholesterol (CH), triglycerides (TG), very low density lipoprotein (VLDL) fraction and increase in high density lipoprotein (HDL) cholesterol, HDL3-CH and apolipoprotein AI concentrations was observed. In type IIa and IIb HLP low density lipoprotein (LDL) cholesterol and apolipoprotein B levels decreased while in type IV increased.

The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome.

In order to establish the role of insulin in the pathogenesis of lipid abnormalities in hyperandrogenic women with the polycystic ovary syndrome (PCO) 49 women aged 18 to 35 yr with a normal glucose tolerance test were studied. They were divided into two groups: 27 women with PCO (9 obese and 18 nonobese), and 22 healthy women (12 with simple obesity and 10 with normal body weight). In the PCO group, the fasting insulin levels and the insulin response to oral glucose load were higher than in the matched controls.

[Lovastatin in the treatment of primary hypercholesterolemia].

The results of 12 weeks treatment of primary hyperlipidemias with Lovastatin are presented. This drug belonging to a new generation of hypercholesterolemic drugs inhibits the endogenous synthesis of cholesterol by means of inhibiting the HMG-CoA reductase. The sample consisted of 30 men aged 28-68 years: in 17 of them heterozygotic familial hypercholesterolemia (FH) was diagnosed and in 13--primary non familial hypercholesterolemia (NFH).

Lipoprotein fractions in idiopathic hyperlipoproteinaemia.

The purpose of the study was an assessment of the lipid and protein composition of very low density lipoproteins (VLDL) in hyperlipoproteinaemias type IIa, IIb, III and IV. Besides that, cholesterol was determined in low density lipoproteins (LDL) and high density lipoproteins (HDL). Fifty-seven patients with idiopathic hyperlipoproteinaemia and nineteen subjects without lipid metabolism disturbances were studied.